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In Brief
L-proline accumulates in human disease,
but how it causes neural dysfunction is
unknown. Here, Crabtree et al. provide
evidence that L-proline is a GABA-
mimetic and find that disease-relevant
concentrations impair GABA production
leading to deficits in sustained GABA-
ergic transmission and gamma
oscillations.
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Proline dehydrogenase (PRODH), which degrades
L-proline, resides within the schizophrenia-linked
22q11.2 deletion suggesting a role in disease. Sup-
porting this, elevated L-proline levels have been
shown to increase risk for psychotic disorders.
Despite the strength of data linking PRODH and
L-proline to neuropsychiatric diseases, targets of
disease-relevant concentrations of L-proline have
not been convincingly described. Here, we show
that Prodh-deficient mice with elevated CNS L-pro-
line display specific deficits in high-frequency
GABA-ergic transmission and gamma-band oscilla-
tions. We find that L-proline is a GABA-mimetic and
can act at multiple GABA-ergic targets. However, at
disease-relevant concentrations, GABA-mimesis is
limited to competitive blockade of glutamate decar-
boxylase leading to reduced GABA production.
Significantly, deficits in GABA-ergic transmission
are reversed by enhancing net GABA production
with the clinically relevant compound vigabatrin.
These findings indicate that accumulation of a neuro-
active metabolite can lead to molecular and synaptic
dysfunction and help to understand mechanisms
underlying neuropsychiatric disease.
INTRODUCTION
There are a large number of relatively rare human diseases in
which genetic mutations result in dysfunction of distinct en-
zymes embedded within metabolic networks, leading in turn to
the pathological accumulation of specific metabolites. A subset
of these diseases also manifests neuropsychiatric dysfunction
(Rahman et al., 2013; Nia 2014). Evidence supporting detailed
mechanisms by which these accumulated small-molecule me-
tabolites directly cause neuropsychiatric manifestations, how-
ever, has rarely been convincingly described (Rahman et al.,
2013; Nia 2014). That both clinical pharmaceuticals and drugs
of abuse can acutely cause psychosis in otherwise normal570 Cell Reports 17, 570–582, October 4, 2016 ª 2016 The Author(s)
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tion of certain endogenous small-molecule metabolites might
likewise contribute to psychosis. Although the potential role of
derangements of such metabolites in the pathogenesis of psy-
chosis and other neuropsychiatric phenotypes remains under-
studied, recent metabolomic profiling in schizophrenia cohorts
has suggested a potential contribution of variations of distinct
metabolites in this disease (Yang et al., 2013; Clelland et al.,
2011; Tomiya et al., 2007).
One metabolite accumulation within the CNS in neuropsychi-
atric diseases that may play a causal role in psychosis is the
accumulation of L-proline due to deletion or dysfunction of
PRODH (L-proline dehydrogenase). Individuals with isolated de-
letions or deleterious missense mutations in this gene, or larger
encompassing deletions in the context of 22q11.2 deletion syn-
drome (22q11.2-DS) demonstrate L-proline elevations and
increased risk for psychotic disorders (Clelland et al., 2011;
Raux et al., 2007; Vorstman et al., 2009; Willis et al., 2008; Jac-
quet et al., 2005). Significantly, the severity of hyperprolinemia in
patients correlates with the risk of psychosis and clinical severity
(Raux et al., 2007; Clelland et al., 2011). A substantial body of
clinical data supports that elevated CNS L-proline may cause
neuronal dysfunction by interfering with native neurotransmitter
systems (Willis et al., 2008). In this regard, we noted the chemical
structure of L-proline closely resembles that of GABA, suggest-
ing pathological levels of L-proline might specifically disrupt
normal GABA-ergic function. Here, we provide multiple lines of
evidence that L-proline acts as aGABA-analog and that in hyper-
prolinemic disease competitive inhibition of GAD by elevated
cytosolic L-proline leads to selective dysfunction in high-fre-
quency GABA-ergic transmission. Consistent with deficits in
high-frequency GABA-ergic drive, in vivo evaluation of network
performance revealed specific and robust deficits in gamma os-
cillations. Our results highlight a unique mechanism of neuronal
dysfunction in psychiatric disorders whereby cytosolic accumu-
lation of a neuroactive metabolite disrupts neurotransmitter
synthesis leading to a specific synaptic dysfunction. This finding
raises the possibility of a potentially broader, important con-
tribution of both GABA-mimetic and other neuroactive metabo-
lites in accounting in part for the large genetic and neural hetero-
geneity of neuropsychiatric disease (Rodriguez-Murillo et al.,
2012)..
commons.org/licenses/by/4.0/).
RESULTS
Isolated Deficits in Sustained GABA Release in Mice
with Elevated CNS L-Proline
To look for possible alterations in evoked synaptic transmission
caused by L-proline accumulation within the CNS, we performed
patch-clamp recordings from layer II/III pyramidal neurons of the
medial prefrontal cortex (mPFC) in acute brain slices prepared
from 4- to 6-week-old hyperprolinemic Prodh/ mice and
wild-type (WT) littermates (Gogos et al., 1999). We chose to
examine evoked synaptic transmission at layer II/III pyramidal
neurons as action potential-mediated neurotransmission be-
tween neurons within this layer is believed to be critically
involved in local network computations in the PFC, a brain region
that has been strongly implicated in the pathophysiology of
schizophrenia and psychosis (Uhlhaas and Singer, 2010; Bartos
et al., 2007).
We assessed electrically evoked GABA-ergic synaptic trans-
mission at layer II/III pyramidal cells by stimulating in layer II
near the boundary between layer I and layer II, approximately
75–150 mm from the soma of the recorded pyramidal neuron
and performing whole-cell voltage-clamp recordings at 0 mV in
the presence of CNQX (10 mM) and d-APV (50 mM) to ensure
isolation of monosynaptic GABA-ergic transmission. Baseline
GABA-ergic transmission (single-stimulus-evoked inhibitory
postsynaptic currents [IPSCs]) was unaltered in Prodh/ mice
(Figure S1A). We also evaluated short-term synaptic plasticity
with a paired-pulse stimulation paradigm employing inter-stim-
ulus intervals ranging from 25 ms to 1 s. We found that paired-
pulse ratios of the amplitudes of IPSCs were not significantly
different between genotypes (Figures 1A and 1B; p > 0.05 at all
inter-stimulus intervals, unpaired t test), indicating that the pre-
synaptic probability of GABA release was unaltered in Prodh/
mice. Upon assessing depression of the amplitude of IPSCs dur-
ing physiologically relevant stimulus trains, however, we found
significantly increased synaptic depression in Prodh/ mice at
both 10 and 33 Hz (Figures 1C, 1D, S2A, and S2B; 10 Hz: p =
0.042; 33 Hz: p = 0.038, two-way rANOVA [repeated measures
ANOVA]), suggesting the possibility of presynaptic depletion of
GABA (Zucker and Regehr, 2002).
We then examined whether synaptic alterations were con-
fined to GABA-ergic transmission in hyperprolinemic mice. We
assessed evoked glutamatergic transmission with whole-cell
voltage-clamp recordings at 70 mV—close to the GABA-A re-
ceptor reversal potential—to isolate glutamatergic transmission.
Baseline transmission (single-stimulus evoked excitatory post-
synaptic currents [EPSCs]) was unaltered (Figure S1B). Similar
to GABA-ergic transmission, we also found that paired-pulse ra-
tios of the amplitudes of EPSCs were not significantly different
between genotypes (Figures 1E and 1F; p > 0.05 at all inter-stim-
ulus intervals, unpaired t test) indicating that the presynaptic
probability of glutamate release was likewise unaltered in
Prodh/ mice. In contrast to GABA-ergic transmission, how-
ever, we found that the depression of the amplitude of the EPSCs
during stimulus trains was not significantly different between ge-
notypes (Figures 1G, 1H, S2C, and S2D; 10 Hz: p = 0.73; 33 Hz:
p = 0.96, two-way RM ANOVA), suggesting that presynaptic
depletion of releasable glutamate during trains was unalteredin Prodh/ mice. In summary, while evoked synaptic transmis-
sion was largely normal at layer II/III pyramidal neurons in the
mPFC of Prodh/ mice, these mice displayed a specific deficit
in sustained, high-frequency GABA-ergic synaptic transmission
as evidenced by increased synaptic depression.
L-Proline Is a Structural Homolog of GABA and Is
GABA-Mimetic
We noted that the chemical structure of L-proline closely resem-
bles that of GABA (Figure 2A), and this similarity might underlie
the GABA-ergic specificity of synaptic dysfunction observed in
Prodh/ mice. We first explored the possibility that L-proline
might neuroactively interfere with GABA-A or GABA-B receptor
function and lead to the synaptic alterations we observed. While
direct measures of extracellular L-proline levels in the brains of
patients with hyperprolinemia are lacking, indirect measures
strongly suggest that L-proline levels are very unlikely to exceed
30 mM in this extracellular compartment (Phang et al., 2001). Em-
ploying whole-cell voltage-clamp recordings from HEK293 cells
heterologously expressing GABA-A receptors, we found that
while high, millimolar concentrations of L-proline could activate
GABA-A receptors (Figures 2B–2D: EC50: 8.3 mM, a1b1g2;
5.4 mM, a5b1g2), even 100 mM L-proline—a concentration
exceeding pathophysiologically relevant extracellular CNS
L-proline levels—could not detectably act at these channels.
Furthermore, even millimolar concentrations of L-proline only
weakly activated GABA-A receptors at normal resting mem-
brane potentials (e.g., 70 mV, Figure 2B), with L-proline-
evoked activation being strongly favored at significantly depolar-
ized potentials (Pavlov et al., 2009) (Figure 2B). Qualitatively
similar results obtained from parallel whole-cell recordings in
cultured cortical neurons confirmed these findings (data not
shown). Consistent with our findings in cultured neurons, record-
ings in layer II/III pyramidal neurons revealed no evidence sug-
gesting significantly altered tonic activation of GABA-A receptor
currents as both input resistance and resting membrane poten-
tial of these neuronswere unaltered inProdh/mice (Figure S3).
Recordings assessing GABA-B receptor combinations heterolo-
gously co-expressed with a G-protein-coupled inwardly recti-
fying potassium channel similarly revealed that, while 10 mM
L-proline could robustly activate GABA-B receptors (Figures
2E and 2F), disease-relevant extracellular CNS concentrations
did not evoke detectable GABA-B-mediated responses (Fig-
ure 2F). Taken together, results obtained at disease relevant
extracellular L-proline concentrations strongly argue against
GABA-A or GABA-B receptors as pathophysiologically relevant
targets of L-proline in human disease.
To better localize the site of L-proline-mediated dysfunction,
we carried out additional assessments of GABA-ergic function.
Immunohistochemistry in WTmouse mPFC showed that PRODH
is normally widely expressed in neurons, including PV+ GABA-er-
gic neurons (Figures 3A, 3B, S4A, and S4B). Although there were
nomarked alterations in either the number or distribution of either
GAD67+ or parvalbumin positive (PV+) interneurons in prelimbic
mPFC in Prodh/ mice (data not shown), localization of PRODH
in GABA-ergic interneurons—including PV+ interneurons—sug-
gests that PRODH dysfunction and L-proline accumulation could
directly impact interneuron function. Indeed, our initial synapticCell Reports 17, 570–582, October 4, 2016 571
Figure 1. Sustained GABA-Ergic Transmission at mPFC L2/3 Pyramidal Cells Is Deficient in Mice with Elevated L-Proline
(A) Paired-pulse ratio of IPSCs was unchanged in Prodh/ mice (red) compared to WT mice (black). Representative traces from single recordings are shown.
Traces were normalized to first response.
(B) Summary data (mean ± SEM) of paired-pulse ratios of IPSCs (WT n = 8; Prodh/ n = 15; p > 0.25 at all tested intervals; t test, unpaired).
(C) Synaptic depression of IPSCs during 33-Hz stimulus trains was greater in Prodh/ mice (red) versus WT mice (black). Representative traces from single
recordings were normalized to first evoked response. Vertical lines, stimulus artifacts. Traces shown were 1-s duration.
(D) Summary data (mean ± SEM) of IPSC during 33-Hz stimulus train, responses to first five and last five stimuli during a 1-s stimulus train (WT n = 11; Prodh/
n = 10, p = 0.038, two-way RM ANOVA; *p < 0.05, **p < 0.01, Bonferroni post hoc analysis).
(E) Paired-pulse ratio of EPSC was unchanged in Prodh/ mice compared to WT mice.
(F) Summary data (mean ± SEM) of paired-pulse ratios of EPSCs (WT n = 8; Prodh/ n = 6; p > 0.45 at all tested intervals; t test, unpaired).
(G) Synaptic depression of EPSCs during 33-Hz stimulus trains was unchanged in Prodh/ mice and normalized to first evoked response. Traces were 1 s in
duration.
(H) Summary data (mean ± SEM) of EPSC amplitudes during a 33-Hz stimulus train showing response to first five and last five stimuli during 1-s stimulus train (WT
n = 10; Prodh/ n = 9, p = 0.96, two-way RM ANOVA; p > 0.05 at all stimuli, Bonferroni post hoc analysis). See also Figures S1 and S2.
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Figure 2. L-Proline Activates GABA-A and
GABA-B Receptors at Supra-physiological
Concentrations
(A) L-proline (left) and GABA (right).
(B) Current-voltage relation for GABA (100 mM,
black) and L-proline (1 mM, red) activation of
a5b1g2 GABA-A receptors in HEK293 cells.
Representative traces from same cell are shown.
L-proline-evoked current was normalized to
maximal GABA-evoked current at 100 mV. Inset,
high dose of L-proline (30 mM) evokes inward
current at 90 mV and is blocked by bicuculline
(10 mM). Scale bar, 25 pA, 5 s.
(C) Summary data (mean ± SEM) of L-proline
activation of a5b1g2 GABA-A receptors at +50 mV
(n = 8, EC50 = 5.4, nH = 1.8). Starred arrow,
maximal disease-relevant extracellular L-proline.
(D) Summary data (mean ± SEM) of L-proline
activation of a1b1g2 GABA-A receptors (n = 7,
EC50 = 8.3, nH = 1.3).
(E) Current-voltage relation for GABA (100 mM,
black, 1) and L-proline (1 mM, red, 2 and 20) acti-
vation of Kir-3.1/3.2 currents through GABA-B 1A/
2 receptors in HEK293 cells. Representative traces
from same cell are shown. Trace 20, L-proline-
evoked current normalized to maximal GABA-
evoked current at 100 mV.
(F) Summary data (mean ± SEM) of GABA and
L-proline activation of Kir-3.1/3.2 currents through
GABA-B 1A/2 (black, n = 8) and 1B/2 (gray, n =
10) receptors. GABA-evoked GABA-B responses
before (t = 0) and after (END) evaluation of L-pro-
line responses are shown. See also Figure S3.findings were strongly suggestive of a presynaptic mechanism
involving enhanced depletion of releasable GABA in Prodh/
mice (Figures 1C, 1D, S1A, S2A, and S2B). Therefore, we as-
sessed this possibility further. Although accelerated IPSC decay
kinetics could cause reduced synaptic summation leading to an
observation of enhanced synaptic depression similar to that
observed in Prodh/mice, comparison of IPSC decay rates dur-
ing stimulus trains revealed no differences between genotypes,
further indicating that postsynaptic GABA receptor function is
largely unaltered in hyperprolinemic mice, thus ruling out this po-
tential post-synaptic mechanism (Figures 3C and 3D; IPSC decay
rate, 10 Hz: p = 0.51; 33 Hz: p = 0.15, two-way RM ANOVA). We
next indirectly probed presynaptic function further to determine
whether observed deficits in sustained GABA-ergic transmission
might be due to a deficit in releasable GABA in Prodh/ mice.
Enhancement of extracellular accumulation of synaptically
released GABA through GAT-1 blockade (NNC-711, 10 mM) re-
vealed markedly reduced and delayed summation of IPSCs dur-
ing high-frequency (33 Hz) stimulus trains in Prodh/ mice
compared to WT mice consistent with a deficit in presynaptic
GABA under conditions of high-demand release (Figures 3E–
3G; maximal response, p = 0.042; latency, p = 0.018, unpaired t
test). Taken together, the results of synaptic experiments argue
strongly that Prodh/ mice have a specific deficit in presynapticGABA release under conditions of high-demand synaptic release
(Figures 1, S1, S2, and 3C–3G).
We next considered potential physiologically relevant in vivo
consequences arising from the deficits in high-frequency sus-
tained GABA-ergic transmission we observed in vitro. A number
of studies have suggested that sustained high-frequency GABA-
ergic drive arising from fast spiking PV+ interneurons is respon-
sible for the generation of gamma oscillations (Cardin et al.,
2009; Sohal et al., 2009; Bartos et al., 2007; Vreugdenhil et al.,
2003). Because Prodh/ mice showed specific deficits in
GABA-ergic synaptic transmission during high-frequency stim-
ulus trains and PRODH is expressed in PV-positive interneurons,
we hypothesized that gamma oscillations would be impaired in
Prodh/mice.We tested this hypothesis by recording local field
potentials (LFPs) in mPFC of Prodh/ mice and WT littermates
during performance of a linear maze task (Figure 4). We found
a robust reduction in 30–80 Hz gamma power in Prodh/
mice (Figures 4A, 4C, and 4D; mean normalized power, WT:
2.0 ± 0.1, Prodh/: 1.4 ± 0.1; Wilcoxon rank-sum test, p =
0.000174, Bonferroni corrected). Low-frequency power was
not significantly affected (Figures 4B–4D; mean 1–4 Hz power,
WT: 110.3 ± 9.6, Prodh/: 117.3 ± 3.4, p = 0.14; mean
4–12 Hz power, WT: 32.5 ± 2.4, Prodh/: 35.8 ± 2.1, p = 0.21;
mean 12–30 Hz power, WT: 20.5 ± 1.4, Prodh/: 19 ± 0.5,Cell Reports 17, 570–582, October 4, 2016 573
Figure 3. GABA Transmission Deficits in Prodh/ Mice Arise Presynaptically
(A) WT prelimbic mPFC at L1/2 boundary showing PRODH co-localizes with neuronal marker, NeuN in a large fraction of L2/3 neurons (scale bar, 100 mm).
(B) PRODH co-localizes with GABA-ergic marker PV in L2/3 (scale bar, 50 mm).
(C) Summary data (mean ±SEM) of IPSC decay time constants (t) during 10-Hz stimulus trains unchanged in Prodh/mice. Analysis of recordings in Figure S2 is
shown. WT, black; Prodh/, red (WT n = 8; Prodh/ n = 7, p = 0.51, two-way RM ANOVA; p > 0.05 at all stimuli, Bonferroni post hoc analysis).
(D) Summary data of IPSC decay rate during 33-Hz stimulus trains unchanged in Prodh/mice. Analysis of recordings in Figures 1C and 1D (WT n = 11; Prodh/
n = 10, p = 0.15, two-way RM ANOVA; p > 0.05 at all stimuli, Bonferroni post hoc analysis).
(E) Summation of IPSCs during 33-Hz stimulus train in presence of GAT-1 blocker (NNC-711, 10 mM)was reduced and delayed inProdh/. Representative traces
from single recordings were normalized to first evoked response. Scale bar, 500 ms.
(F) Summary data (mean ± SEM) of maximal IPSC summation current (normalized to first response) during 33-Hz trains with GAT-1 blockade is reduced in
Prodh/ mice (WT n = 6; Prodh/ n = 6, p = 0.042, unpaired t test).
(G) Summary data of latency to maximal summation during 33-Hz trains with GAT-1 blockade was delayed in Prodh/mice (WT n = 6; Prodh/ n = 6, p = 0.018,
unpaired t test). See also Figure S4.
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Figure 4. Prodh/ Mice Exhibit Gamma Power Deficits in mPFC
(A) Representative LFP traces from WT (left) and Prodh/ (right) mice. Top
traces, raw LFP recordings. Bottom traces, filtered 30- to 80-Hz gamma os-
cillations. LFPs were normalized by signal root mean square.
(B) Normalized power spectra (mean ± SEM) between Prodh/ mice (n = 7,
red) and WT (n = 9, black). Power spectra calculations used parameters
optimized for either low (left) or high frequencies (right).
(C) Z-scored power spectra in (B) relative to WT power.
(D) Summary data (mean ±SEM) of mean power across frequency ranges. WT,
black;Prodh/, red. Gamma power (30–80 Hz) was reduced in Prodh/mice
(WT n = 9; Prodh/ n = 7; 1–4 Hz: p = 0.14; 4–12 Hz: 0.21; 12–30 Hz: 0.76;
30–80 Hz: p = 0.000174; Wilcoxon rank-sum test, ***p < 0.001, Bonferroni
corrected).p = 0.76, Bonferroni corrected). Interestingly, in concordance
with our in vitro finding that Prodh/ mice displayed enhanced
synaptic depression in response to 33Hz stimulation, thesemice
showed the most profound power deficits at38 Hz (Figure 4C).
Taken together with in vitro findings, these in vivo findings pro-
vide evidence consistent with the deficit in high-frequency
GABA-ergic transmission observed in vitro in Prodh/ mice as
a likely contributing factor to the deficits in gamma oscillations
observed in vivo. Collectively, these findings provide both
in vitro and in vivo evidence for an important role for processes
downstream of the Prodh gene in the generation of high-fre-
quency neural activity. Further, given the important role gamma
oscillations play in organizing local network activity during cogni-
tive tasks (Roux and Uhlhaas, 2014; Uhlhaas and Singer, 2010;
Chen et al., 2014), these findings strongly suggest that deficits
in high-frequency GABA-ergic transmission could contribute to
cognitive deficits both in patients with isolated hyperprolinemia
and in the large fraction of 22q11-DS patients that also present
with hyperprolinemia (Raux et al., 2007; Clelland et al., 2011;Wil-
lis et al., 2008; Jacquet et al., 2002, 2005; Kempf et al., 2008; Li
et al., 2008; Roussos et al., 2009).
Cytosolic L-Proline Elevations Impair GABA Production
and Synaptic Transmission Due to GAD Blockade
We next sought to determine the mechanism of L-proline-medi-
ated presynaptic dysfunction that led to the deficits in sustained
GABA-ergic transmission. Although our results indicated that
GABA-A and GABA-B receptors were not credible targets of
L-proline at disease relevant concentrations (Figures 2B–2F and
S3), activation of these GABA receptors with millimolar levels of
L-proline indicated that L-proline is GABA-mimetic and sug-
gested it could potentially interfere with other GABA-ergic targets
regulating synaptic function. We also noted that the vast majority
of small molecule metabolites—including L-proline—are normally
preferentially confined (typicallywith a 10- to 100-fold enrichment)
to the intracellular compartment as opposed to the extracellular
space (Bennett et al., 2008, 2009). Furthermore previous studies
indicating a normal level of 1 mM total free brain L-proline
increasing to 5–6 mM in Prodh/ mice in the context of low
micromolar levels of extracellular CNS L-proline indicated that
the majority of L-proline accumulation in the cerebral cortex of
Prodh/ mice must likewise be preferentially confined to the
intracellular compartment and at concentrations close to 5 mM
(Gogos et al., 1999). Given our evidence of L-proline GABA-
mimesis (Figure 2) and the significant structural homology be-
tween L-proline and GABA (Figure 2A), we considered possible
intracellular GABA-ergic targets of L-proline that could account
for the apparent selective reduction in presynaptic releasable
GABA in the PFC of Prodh/ mice.
We hypothesized that elevated cytosolic L-proline in Prodh/
GABA-ergic neurons might reduce GABA synthesis through
competitive inhibition of glutamate decarboxylase (GAD). In
support of this hypothesis, we noted the enhanced synaptic
depression of GABA-ergic responses during stimulus trains we
observed in Prodh/ mice was remarkably reminiscent of the
enhanced GABA-ergic synaptic depression during stimulus
trains that was the most prominent synaptic dysfunction in
Gad65/ mice (Tian et al., 1999).Cell Reports 17, 570–582, October 4, 2016 575
To test whether L-proline inhibited GAD synthesis of GABA,
we performed in vitro assays of GABA production utilizing both
heterologously expressed human GAD67 as well as GAD iso-
lated from a mouse PFC cytosolic fraction. For these assays,
cytosolic L-proline concentrations were inferred from previous
measures of whole-brain (wet brain tissue) L-proline in both
WT and Prodh/ mice (Gogos et al., 1999). As intracellular vol-
ume is the dominant contribution to brain volume (far exceeding
extracellular space in which L-proline unlikely exceeds 30 mM in
mutant mice, Gogos et al., 1999; Phang et al., 2001), these in-
ferred values of 5–6 mM cytosolic L-proline levels (compared
to a normal cytosolic L-proline concentration of 1 mM) repre-
sent conservative estimates of neuronal cytosolic L-proline
concentrations.
In vitro GAD activity reactions were incubated at 37C for 1 hr
and employed physiological levels of L-glutamate (5mM) as sub-
strate and either normal (1 mM) or hyperprolinemic levels (5 mM)
of cytosolic L-proline (Gogos et al., 1999). High-performance
liquid chromatography (HPLC) analysis of the reaction products
of these assays showed that reactions that included 5 mM
L-proline had reduced GABA synthesis by approximately 25%
compared to those that included 1 mM L-proline (Figures 5A
and 5B; hGAD67: p = 4.3 3 108; mouse PFC GAD fraction:
p = 0.013, unpaired t tests). A more comprehensive inhibition
study further indicated that L-proline inhibition of GAD67 was
competitive and characterized by a Ki of 7.8 mM (Figure 5C).
These results indicate that pathophysiological concentrations
of L-proline can inhibit GAD-dependent synthesis of GABA and
that such GAD blockade by elevated cytosolic L-proline in
Prodh/mice may be responsible for the deficits in GABA-ergic
synaptic transmission we observed during high-frequency stim-
ulus trains (Figures 1 and S2).
We next looked for more direct evidence that L-proline
blockade of GAD-dependent GABA synthesis could be function-
ally significant and responsible for the enhanced depression in
GABA-ergic synaptic transmission observed during high-fre-
quency stimulus trains. To address this possibility, we first tested
whether acute pharmacological blockade of GAD in themPFC of
WT mice could phenotypically mimic the GABA release deficits
observed in Prodh/ mice. To mimic L-proline blockade of
GAD in Prodh/ mice, acute WT brain slices were pre-incu-
bated with the competitive GAD antagonist 3-mercaptopro-
pionic acid (3-MPA, 1 mM) for 2 hr and postsynaptic GABA-ergic
responses to 33-Hz stimulus trains were then assessed in the
continuous presence of 100 mM3-MPA.We found that the ampli-
tude of the IPSCs during 33-Hz stimulus trains showed signifi-
cantly increased synaptic depression in WT brain slices treated
with 3-MPA compared to those in untreated WT slices (Figures
5D and 5E; p = 0.00090, two-way RM ANOVA). This result indi-
cated that GAD blockade leads to enhanced synaptic depres-
sion similar to that observed in Prodh/ mice.
Furthermore, in contrast to findings in WT, GAD blockade with
3-MPA in Prodh/ brain slices did not lead to further increases
in synaptic depression of IPSCs during 33-Hz stimulus trains
(Figure 5E; p = 0.87, two-way RM ANOVA) consistent with a
near-maximal impact of basal GAD-blockade upon GABA-ergic
transmission in Prodh/ mice. This result further suggests that
the observed partially sustained high-frequency GABA-ergic re-576 Cell Reports 17, 570–582, October 4, 2016sponses (Figures 1C, 1D, and 5E–5G) are likely due to emer-
gence of predominantly GAD-independent, GABA-conserving
compensatory mechanisms. A trend toward elevated GAD activ-
ity in PFC cytosolic fractions isolated from Prodh/ mice (Fig-
ure S5, p = 0.12, unpaired t test) additionally suggested the pos-
sibility that in vivo blockade of GAD in Prodh/micemay trigger
a compensatory upregulation of GAD expression. This finding
suggests that the enhanced short-term depression observed
in Prodh/ mice is not due to reduced expression of GAD
isoforms.
Importantly, we also assessed whether enhancing net GABA
production reverses the deficits in sustained GABA-release. In
parallel, experiments employing an identical stimulus paradigm,
enhancing net GABA production in Prodh/ mice with the irre-
versible GABA-transaminase inhibitor vigabatrin (1,500 mg/kg,
intraperitoneal [i.p.] injection 2.5 days prior to recording; Gale
and Iadarola, 1980) led to the near elimination of the enhanced
synaptic depression in response to 33 Hz stimulus trains seen
in untreated (Figure 1) or vehicle-treated Prodh/ mice (Figures
5F and 5G; p = 0.041, two-way RM ANOVA; no effect on short-
term plasticity during the first five responses, p = 0.13, two-
way RM ANOVA).
These results obtained with pharmacological manipulations of
GABA production in brain slices support that the enhanced
GABA-ergic synaptic depression during sustained high-fre-
quency stimulation results from a deficit in GABA production in
Prodh/ mice. In concert with in vitro results showing L-proline
blockade of GAD (Figures 5A–5C), these results strongly support
the notion that this enhanced GABA-ergic synaptic depression
arises due to deficits in GABA production resulting from signifi-
cant in vivo blockade of GAD by L-proline accumulated within
the cytosol of inhibitory neurons.
DISCUSSION
Our findings suggest a mechanism of neuronal dysfunction
potentially important in the pathogenesis of schizophrenia and
other neuropsychiatric disorders whereby accumulation of an
endogenous neuroactive metabolite in disease leads to severe
and specific deficits in synaptic function and neural circuit per-
formance. Specifically, our results show that L-proline is a
GABA-analog and that L-proline accumulation in the cytosol of
GABA-ergic neurons causes competitive inhibition of GAD lead-
ing to deficient GABA production. This results in a specific func-
tional impact limited to deficits in sustained, high-frequency
GABA-ergic transmission, a high synaptic demand condition un-
der which GABA production via GAD is critical to maintaining
ongoing transmission (Ha´jos et al., 2004; Bartos et al., 2007;
Hefft and Jonas, 2005; Tian et al., 1999; Wang et al., 2013).
Similarly circumscribed deficits have been previously described
in GAD65-null mice (Tian et al., 1999). By contrast, lower GABA-
demand conditions such as baseline transmission (single
stimulus) and very short-term plasticity (paired-pulse ratio) are
unchanged, as was similarly observed in GAD65-null mice
(Tian et al., 1999).
During sustained GABA-ergic transmission, GABA released
from presynaptic terminals must be replenished either by de
novo GABA synthesis via GAD or by GABA reuptake from the
Figure 5. L-Proline Is a GABA-Analog that Acts as a Competitive Inhibitor of GAD
(A) Summary data (mean ± SEM) of in vitro GABA production with recombinant human GAD67. All reactions, 5 mM L-glutamate. Reactions with 1 (black) or
5 (red) mM L-proline to approximate normal and hyperprolinemic disease cytosolic L-proline levels, respectively (1 mM L-proline, n = 17, 5 mM L-proline, n = 15,
p = 4.3 3 108, unpaired t test) are shown.
(B) Summary data of GABA production employing a GAD-containing cytosolic fraction from mouse PFC. *p < 0.05 (1 mM L-proline, n = 5; 5 mM L-proline, n = 5,
p = 0.013, unpaired t test).
(C) Lineweaver-Burk plot of GABA production of human GAD67 comparing activity in 0 (black, n = 5) and 5 (red, n = 5) mM L-proline. Linear regression fits, solid
lines, and equations are shown. Data were well fit (0 mM L-proline, R2 = 0.990; 5 mM L-proline, R2 = 0.988). Comparison of fits, p = 0.0045. Near-identical
y intercepts of linear fits indicate L-proline inhibition is competitive.
(D) Synaptic depression of IPSCs during 33-Hz stimulus trains was enhanced in WT brain slices treated with the GAD blocker, 3-MPA (100 mM, gray trace).
Representative traces from single recordings were normalized to the first evoked response. Traces shown, 1 s in duration.
(E) Summary data (mean ± SEM) of IPSC amplitudes during 33-Hz stimulus train showing responses to the first five and last five stimuli during 1-s stimulus train.
WT, black; 3-MPA-treated WT, gray; Prodh/, red; 3-MPA-treated Prodh/, pink (WT, n = 10; WT 3-MPA, n = 11; Prodh/, n = 12; Prodh/ 3-MPA, n = 13.
WT versus Prodh/ p = 0.042; WT versus WT 3-MPA p = 0.00090; Prodh/ versus Prodh/ 3-MPA p = 0.87, two-way RM ANOVAs; *p < 0.05, **p < 0.01,
***p < 0.001, Bonferroni post hoc analysis).
(legend continued on next page)
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extracellular space (principally mediated by GAT-1) as GABA
diffusion from adjacent cellular compartments is insufficient
(Wang et al., 2013). While in principal both mechanisms could
replenish GABA during sustained transmission, reuptake of
GABA via GAT-1 does not appear critical while de novo synthe-
sis by GAD is indispensible (Bragina et al., 2008; Wang et al.,
2013; Tian et al., 1999). As such, blockade of GAD activity by
elevated cytosolic L-proline—which similar to most small mole-
cule metabolites is preferentially sequestered intracellularly
(Bennett et al., 2008, 2009; Gogos et al., 1999)—would be ex-
pected to interfere with sustained GABA-ergic transmission
(Tian et al., 1999; Wang et al., 2013). How GAD hypofunction
and acute GABA depletion exactly lead to enhanced synaptic
depression remains unknown (Tian et al., 1999; Wang et al.,
2013), but mechanisms including kiss-and-run recycling (Ste-
vens and Williams, 2000; Alabi and Tsien, 2013) and rapid endo-
cytosis (Pyle et al., 2000; Ca´rdenas and Marengo, 2010) may be
involved. Bothmechanisms lead to GABA release and vesicle re-
filling within the time course of our depression paradigms and
would likely be sensitive to acute deficiencies in synaptic
GABA production.
The reduced and delayed summation of GABA-ergic events in
Prodh/ mice observed during GAT-1 blockade compared to
robust summation inWTmice also supports a deficit in sustained
availability of presynaptic GABA during high-demand release in
Prodh/ mice (Tian et al., 1999). Further, acute blockade of
GAD in WT mice led to deficits in sustained release similar to
Prodh/mice while enhancing GABA content through blockade
of GABA degradation with vigabatrin significantly rescued sus-
tained GABA-ergic transmission. Notably, while high concentra-
tions of L-proline could robustly activate both GABA-A and
GABA-B receptors—confirming L-proline as a bona fide GABA
analog—this activation was observed only at supra-physiolog-
ical concentrations far exceeding extracellular levels found in
disease (Phang et. al., 2001). These findings largely rule out post-
synaptic GABA-A/GABA-B receptors as possible disease-rele-
vant mediators of the effects of elevated L-proline. Our finding
of unaltered decay kinetics of GABA-ergic synaptic events
further supported this conclusion, again pointing to a presynap-
tic alteration underlying the sustained GABA-ergic transmission
deficit consistent with neurotransmitter depletion (Zucker and
Regehr, 2002).
In addition to our results, the striking correspondence of our
findings to the similarly circumscribed GABA-ergic deficits pre-
sent in the GAD65-null mouse further supports our proposed
mechanism of GAD hypofunction (Tian et al., 1999). While
GABA-ergic transmission has not been assessed GAD67-null
mice (due to non-viability), the specific deficiencies in sustained
GABA release present in GAD65-null mice suggest that GAD65
could be a critical synaptic target of L-proline in vivo. GAD65
is preferentially localized to presynaptic terminals, is synaptic
activity dependent, and is functionally coupled to vGAT and(F) Enhanced synaptic depression of IPSCs during 33-Hz stimulus trains in Prod
abatrin (1,500 mg/kg, i.p. injection 2.5 days prior to recording, pink trace).
(G) Summary data of IPSC amplitudes during 33-Hz stimulus train. Vehicle-treate
two-way RM ANOVA; *p < 0.05, Bonferroni post hoc analysis). See also Figures
578 Cell Reports 17, 570–582, October 4, 2016synaptic vesicles to facilitate vesicular GABA loading (Fenalti
et al., 2007; Esclapez et al., 1994; Jin et al., 2003).
Our findings suggest L-proline’s effect on inhibitory transmis-
sion is specific. We did not detect any alterations in evoked glu-
tamatergic transmission—including duringmoderate to high-fre-
quency stimulus trains—consistent with the substantial shared
structural homology of L-proline with GABA rather than with
glutamate. However, we cannot exclude the possibility that re-
ductions in GABA-ergic transmission due to L-proline may indi-
rectly affect excitatory transmission and plasticity due to reduc-
tions in GABA-ergic modulatory influences (Guetg et al., 2009;
Stell et al., 2007; Sakaba and Neher, 2003). Although we did
not observe such effects, it is possible that such indirect effects
could be revealed under different stimulation paradigms or in
other brain areas.
Here, we have assessed evoked synaptic transmission,
which recapitulates the action potential-mediated neurotrans-
mission responsible for driving moment-to-moment neural cir-
cuit computation. Whether L-proline accumulation also affects
spontaneous synaptic activity (miniature synaptic events) re-
mains to be determined. However, it is notable that GAD hypo-
function present in GAD65-null mice did not affect the frequency
or amplitude of miniature synaptic events (Tian et al., 1999).
Furthermore, our synaptic results showing GABA-ergic baseline
transmission and very short-term plasticity are both unchanged
suggest that the synaptic impact of GAD blockade becomes
functionally apparent only under high GABA demand scenarios
(Tian et al., 1999).
With respect to possible functional outcomes due to GAD hy-
pofunction, the sustained high-frequency GABA release that de-
pends upon intact GAD function and de novo GABA synthesis
(Wang et al., 2013; Tian et al., 1999; Fenalti et al., 2007; Esclapez
et al., 1994; Jin et al., 2003; Bragina et al., 2008) may be most
physiologically relevant for PV+ fast-spiking neurons in which
high-frequency action potentials are translated into high-fre-
quency GABA release (Ha´jos et al., 2004; Bartos et al., 2007;
Hefft and Jonas, 2005; Szabo´ et al., 2010; Hu et al., 2014). In
fact, the in vivo network alterations we found in Prodh/ mice
were consistent with deficits in sustained GABA-ergic transmis-
sion arising from PV+ interneurons.
The network dysfunction we observed that was limited specif-
ically to robust deficits in gamma oscillations supports the rele-
vance of the high-frequency GABA-ergic transmission deficits
we observed in vitro. High-frequency GABA-ergic transmission
from PV+ neurons onto layer II/III pyramidal neurons drives the
generations of gamma oscillations critically involved in local
network computations in the PFC, and deficits in this drive are
expected to lead to deficits in gamma oscillations (Bartos
et al., 2007; Volman et al., 2011). Significantly, dysfunction of
PFC gamma oscillations has been strongly implicated in the
network pathophysiology underlying the cognitive deficits pre-
sent schizophrenia (Uhlhaas and Singer, 2010; Chen et al.,h/ slices (red trace) was reduced with a blocker of GABA degradation, vig-
d Prodh/, red (n = 10); vigabatrin-treated Prodh/, pink (n = 21) (p = 0.041,
S5 and S6.
2014). While the potential role of GAD hypofunction upon net-
work function has not previously been described in GAD-defi-
cient mice, it is notable that models of cortical network function
have predicted that GAD hypofunction leads to enhanced short-
term depression of GABA-ergic transmission and consequent
reductions in the power of gamma oscillations, mirroring both
our in vitro and in vivo findings (Volman et al., 2011).
Furthermore, deficits in pre-pulse inhibition of acoustic startle
and conditioned fear learning are shared as the most prominent
behavioral findings in both Prodh/ mice and GAD65-deficient
mice (Heldt et al., 2004; Gogos et al., 1999; Stork et al., 2003; Pa-
terlini et al., 2005), and both behaviors depend upon intact GAD
function as well as upon PV+ interneuron function (Nguyen et al.,
2014; Wolff et al., 2014). That deficits in sustained high-fre-
quency GABA release are the most prominent electrophysiolog-
ical findings in both of these mutant mouse lines suggests their
shared behavioral dysfunction might arise from shared deficits
in sustained GABA release.
Elevation of L-proline levels in 22q11.2 deletion carriers is
as an important component of the psychiatric risk associated
with this genomic lesion and depends on the presence of
hypomorphic PRODH alleles in the retained copy on the
intact chromosome (Raux et al., 2007; Bender et al., 2005; Chak-
ravarti, 2002; Liu et al., 2002; Willis et al., 2008; Zarchi et al.,
2013). Significantly, the severity of hyperprolinemia in these
patients correlates with risk of psychosis (Raux et al., 2007).
Our findings illuminate mechanisms of L-proline-dependent
dysfunction likely contributing to the psychiatric risk associated
with 22q11.2 deletions and provide insights into GABA-ergic
dysfunction emerging as a result of this genomic lesion. These
findings also suggest straightforward approaches to targeted
therapies that could be used to ameliorate or prevent GABA-
ergic dysfunction. Additionally our results have broader im-
plications for the genetic and neural mechanisms underlying
psychosis.
First, reduced expression of both GAD67 and GAD65 have
been repeatedly implicated in studies of schizophrenia cohorts
suggesting that deficient sustained GABA release resulting
from GAD hypofunction, such as observed both in GAD65-null
mice as well as here in Prodh/ mice, could significantly con-
tribute to related disease dysfunction (Akbarian et al., 1995;
Heckers et al., 2002; Benes et al., 2007; Rocco et al., 2016;
Tian et al., 1999). Significantly, parallel studies have also
commonly found reductions and alterations in PV+ interneurons
(Hashimoto et al., 2003; Knable et al., 2004; Zhang and Rey-
nolds, 2002). Further supporting a relevant pathological role, al-
terations in PV+ neurons have additionally been observed in
diverse mouse models of schizophrenia (Fe´nelon et al., 2013;
Niwa et al., 2010; Carlson et al., 2011; Del Pino et al., 2013;
Wen et al., 2010). Functional alterations of PV+ neurons, which
are uniquely designed for high-frequency, sustained GABA
release (Hefft and Jonas, 2005; Szabo´ et al., 2010; Hu et al.,
2014; Bartos et al., 2007; Ha´jos et al., 2004), may represent an
important and relevant source of synaptic dysfunction in schizo-
phrenia. Indeed, the fidelity of sustained GABA release from PV+
interneurons appears critical to network and behavioral dysfunc-
tion found in this disease (Constantinidis et al., 2002; Uhlhaas
and Singer, 2010).Second, studies have previously implicated elevated L-proline
in susceptibility for schizophrenia and related disorders and
showed severity of hyperprolinemia correlates with risk and
severity of disease (Clelland et al., 2011; Willis et al., 2008; Jac-
quet et al., 2002, 2005; Kempf et al., 2008; Li et al., 2008; Rous-
sos et al., 2009). Importantly, in addition to targeted studies that
have implicated L-proline levels in schizophrenia risk (Clelland
et al., 2011; Tomiya et al., 2007), a recent blind metabolomic
study of schizophrenics, while not identifying L-proline itself,
identified two metabolite risk candidates—5-oxoproline and
L-pipecolic acid—that bear striking structural homology to
L-proline (Figure S6) (Yang et al., 2013; two out of the 22 total
risk metabolites identified by this study). In this regard, it is
further notable that L-pipecolic acid accumulates in pyridoxine
dependent seizures—a disease long speculated to result from
GAD hypofunction (Scriver and Whelan, 1969)—due to antiquitin
deficiency and that 5-oxoproline accumulates in glutathione syn-
thetase deficiency, ametabolic disease also associated with sei-
zures and psychosis (Robertson et al., 1991). In the context of
our results, these findings suggest the possibility of a broader
and important contribution of both GABA-mimetic as well as
other neuroactive metabolites in explaining in part the large ge-
netic heterogeneity of neuropsychiatric disease (Rodriguez-Mu-
rillo et al., 2012). This also points toward the merit of exploring
the potential of targeted and precise therapeutic interventions
based on the genetic and metabolic profile of patients including
reevaluation of the many clinically available pharmaceuticals
know to enhance GABA-ergic function.
EXPERIMENTAL PROCEDURES
Animals
All animal procedures were carried out in accordance with and approved by
the Columbia University Institutional Animal Care and Use Committee. Exper-
iments were performed on homozygous Prodh-deficient male mice and their
wild-type (WT) littermates. The generation of the Prodh/ mice has been
described previously (Paterlini et al., 2005).
Acute Brain Slice Electrophysiology
Medial prefrontal cortical slice preparation has been previously described
(Fe´nelon et al., 2013). All mice were 4- to 6-week-old male littermates. All ex-
periments employed whole-cell, voltage-clamp recordings from prelimbic
and infralimbic mPFC layer II/III pyramidal neurons. Evoked synaptic re-
sponses were elicited with electric stimulation with a bipolar stimulating
electrode positioned within layer II approximately 75–150 mm lateral from
the recorded neuron. Neurons were held in voltage-clamp at 70 mV to
assess evoked excitatory synaptic responses and at 0 mV in the presence
of CNQX (10 mM) and AP-V (50 mM) to assess evoked inhibitory synaptic
responses.
Recordings Employing Heterologously Expressed of GABA-A and
GABA-B Receptors
HEK293 cells were transfected with indicated cDNA plasmids using Lipofect-
amine 2000 (Invitrogen) following the manufacturer’s instructions. Transfected
cells were used for voltage-clamp recordings 2–6 days after transfection.
In Vivo Neurophysiology
Three- to 4-month-old Prodh/ mice and WT littermates were anesthetized
with isoflurane, placed in a stereotaxic apparatus, and implanted with a
tungsten wire field electrode or a bundle of 15 tungsten wire stereotrodes in
the mPFC. Wires were connected to a 16- or 36-channel electrode interface
board (Neuralynx) fixed to the skull with dental cement. After surgical recovery,Cell Reports 17, 570–582, October 4, 2016 579
habituation, and task training in a linear track, local field potentials (LFPs) were
recorded (Digital Lynx system) while mice were running in the linear track on
2 days, 20 min on each day. The multitaper method was used to compute po-
wer spectral density when running speed was 20–25 cm/s.
GAD Activity Assays
GAD fractions were obtained from either heterologous expression in BL21
E. coli or from mouse brain homogenates. GAD reactions were carried out at
37C inGAD reaction buffer (100mMKPO4, 1mM2-aminoethylisothiouronium
bromide [AET], and 100 mM of pyridoxal-50-phosphate [pH 7.2]). L-glutamate
was provided as substrate, and L-proline was included in reactions to test
for GAD inhibition. After quenching, reaction products were derivatized and
assessed for GABA content via HPLC.
Statistical Analysis
For comparisons involving repeated measures, two-way ANOVA repeated-
measures analyses were employed with Bonferroni post hoc analysis. For all
other simple comparisons, unpaired t tests were employed that were two
sided except in cases in which there was a directional hypothesis. The mean
power at different frequency bands was compared using Wilcoxon rank-sum
test, with Bonferroni-corrected p values for multiple comparisons.
A full description of these methodologies as well as for immunohistochem-
istry is provided in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.09.029.
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